Shire

Takeda staffers accuse drugmaker of favoring Shire employees during merger: report
Takeda staffers accuse drugmaker of favoring Shire employees during merger: report
Fierce Pharma
Korea
Shire
Takeda
employees
M&A
Flag link:
As Takeda absorbs Shire’s R&D ops, the focus is on replacing a centralized command model with a ‘light touch’ in a restructured global organization
As Takeda absorbs Shire’s R&D ops, the focus is on replacing a centralized command model with a ‘light touch’ in a restructured global organization
Endpoints
Takeda
Shire
R&D
restructuring
M&A
Flag link:
Takeda Eyes Additional Divestitures to Pare Down Shire Deal Debt
Takeda Eyes Additional Divestitures to Pare Down Shire Deal Debt
BioSpace
Takeda
Shire
M&A
Flag link:
In $86M IPO pitch, Mirum spells out plans to turn Shire discards into orphan liver drug successes
In $86M IPO pitch, Mirum spells out plans to turn Shire discards into orphan liver drug successes
Endpoints
Mirum
IPOs
Shire
liver disease
Flag link:
Servier, armed with Shire cancer drugs, builds out vision for U.S. future
Servier, armed with Shire cancer drugs, builds out vision for U.S. future
Fierce Pharma
Servier
oncology
Shire
M&A
Flag link:
Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal
Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal
Fierce Pharma
Takeda
Shire
Novartis
M&A
Xiidra
dry eye disease
Flag link:
Novartis Considers Offer for Takeda Eye-Disease Assets
Novartis Considers Offer for Takeda Eye-Disease Assets
Bloomberg
Novartis
Takeda
Shire
eye disease
M&A
Flag link:
Pharma AbbVie, Shire investors agree to settle lawsuit over scuttled tax-inversion deal
Pharma AbbVie, Shire investors agree to settle lawsuit over scuttled tax-inversion deal
Fierce Pharma
AbbVie
Shire
taxes
tax inversions
M&A
Flag link:
14 Drugs Earn Billions for These Massachusetts Biotechs
14 Drugs Earn Billions for These Massachusetts Biotechs
BioSpace
Massachusetts
Boston
Biogen
Tecfidera
Benepali
Shire
Takeda
Vyvanse
Vertex Pharmaceuticals
Orkambi
Kalydeco
Alexion
Soliris
Strensiq
Sanofi Genzyme
Lantus
Ironwood Pharmaceuticals
Linzess
Flag link:
Case Study: How Shire improved its time-to-market
Case Study: How Shire improved its time-to-market
Pharmaforum
Shire
drug development
time-to-market
Flag link:
Takeda mulling sale of emerging market drugs – report
Takeda mulling sale of emerging market drugs – report
Pharmaforum
Takeda
Shire
M&A
emerging markets
Flag link:
Takeda’s Shire takeover could herald new era of pharma M&A
Takeda’s Shire takeover could herald new era of pharma M&A
Pharmaforum
M&A
Takeda
Shire
taxes
Pfizer
Flag link:
With mega merger season in full swing, Takeda officially swallows Shire
With mega merger season in full swing, Takeda officially swallows Shire
Endpoints
Takeda
Shire
M&A
Flag link:
Takeda builds arsenal for immuno-oncology research, creates cell therapy group
Takeda builds arsenal for immuno-oncology research, creates cell therapy group
Endpoints
Takeda
immuno-oncology
cell therapy
Shire
Flag link:
Shire gears up to battle Allergan's Linzess with new constipation drug Motegrity
Shire gears up to battle Allergan's Linzess with new constipation drug Motegrity
Fierce Pharma
Takeda
Shire
Allergan
chronic idiopathic constipation
Motegrity
Flag link:
A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames
A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames
Endpoints
Takeda
Shire
M&A
Flag link:
Takeda Acquisition Of Shire May Bode Well For R&D Staff
Takeda Acquisition Of Shire May Bode Well For R&D Staff
Forbes
Shire
Takeda
R&D
M&A
Flag link:
Takeda ready to dismiss assets for a total $10bn
Takeda ready to dismiss assets for a total $10bn
GoinPharma
Takeda
Shire
M&A
Flag link:
Takeda could rack up $10B in selloffs after controversial Shire buyout: report
Takeda could rack up $10B in selloffs after controversial Shire buyout: report
Fierce Pharma
Takeda
Shire
M&A
shareholders
Flag link:
Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains
Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains
Endpoints
Takeda
shareholders
Japan
M&A
Shire
Europe
Flag link:

Pages